Brokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) Target Price at $124.18

TransMedics Group, Inc. (NASDAQ:TMDX) has been given a consensus recommendation of “Hold” by the thirteen research firms that are currently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and six have given a buy recommendation to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $124.1818.

TMDX has been the subject of a number of recent research reports. TD Cowen restated a “buy” rating and issued a $120.00 price objective on shares of TransMedics Group in a research note on Wednesday, July 1st. Zacks Research cut shares of TransMedics Group from a “hold” rating to a “strong sell” rating in a research note on Monday, July 6th. Stifel Nicolaus increased their price target on shares of TransMedics Group from $75.00 to $80.00 and gave the stock a “hold” rating in a research report on Thursday, June 18th. Canaccord Genuity Group restated a “buy” rating and set a $124.00 price target on shares of TransMedics Group in a research note on Tuesday, June 30th. Finally, Weiss Ratings downgraded TransMedics Group from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, July 28th.

Insider Activity

In other news, Director Thomas J. Gunderson sold 9,624 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.06, for a total value of $722,377.44. Following the completion of the transaction, the director directly owned 16,642 shares of the company’s stock, valued at approximately $1,249,148.52. This represents a 36.64% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders own 6.90% of the company’s stock.

Institutional Trading of TransMedics Group

A number of large investors have recently bought and sold shares of TMDX. Harvest Fund Management Co. Ltd bought a new position in shares of TransMedics Group during the third quarter valued at $29,000. Allworth Financial LP grew its holdings in shares of TransMedics Group by 74.3% in the 3rd quarter. Allworth Financial LP now owns 265 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares during the last quarter. Parallel Advisors LLC grew its holdings in shares of TransMedics Group by 42.1% in the 4th quarter. Parallel Advisors LLC now owns 280 shares of the company’s stock worth $34,000 after purchasing an additional 83 shares during the last quarter. Ascentis Independent Advisors bought a new stake in shares of TransMedics Group in the 1st quarter worth about $30,000. Finally, North Star Investment Management Corp. acquired a new stake in shares of TransMedics Group during the 1st quarter worth about $30,000. 99.67% of the stock is currently owned by institutional investors.

TransMedics Group Stock Performance

TMDX opened at $90.69 on Friday. The stock’s 50 day simple moving average is $76.32 and its 200-day simple moving average is $95.94. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The stock has a market cap of $3.13 billion, a PE ratio of 23.31 and a beta of 1.90. TransMedics Group has a 1 year low of $60.10 and a 1 year high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its earnings results on Tuesday, August 4th. The company reported $0.44 EPS for the quarter, missing the consensus estimate of $0.50 by ($0.06). TransMedics Group had a return on equity of 15.88% and a net margin of 22.69%.The firm had revenue of $189.95 million during the quarter, compared to the consensus estimate of $184.00 million. During the same period last year, the business earned $0.92 earnings per share. The firm’s revenue for the quarter was up 20.7% compared to the same quarter last year. Sell-side analysts forecast that TransMedics Group will post 1.47 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.